CTLA4 and head and neck squamous cell carcinoma: To our knowledge, this is the first report of OX40, PD-1 and CTLA-4 expression levels in the TIL and peripheral lymphocytes from SCCHN patients and provides rationale for combination therapy with these agents in this disease.